For first-in-human and early-feasibility studies enrolling five to fifteen patients, smaller LATAM markets including El Salvador, Panama, and the Dominican Republic now outpace Brazil and Mexico on first-patient-in. Chile enters the bioaccess(R) FIH country map as the sixth credible LATAM jurisdiction. Plus the FDA Real-Time Clinical Trials pilot information session, Synvia's domestic Brazilian Phase I positioning, and CytomX's Varseta-M dose-optimization completion.
El Salvador · Panama · Dominican Republic · Chile · Brazil · United States
bioaccess(R) | Global Trial Accelerators(TM) | Fast-Tracking First-in-Human Trials, Anywhere
Read the full newsletter online here.
---
This week the operational case for Latin American early-phase trials reframed itself around something other than the region's two biggest jurisdictions. With Brazil's new framework now two weeks operative and Argentina's 62-day cap still awaiting empirical confirmation, the story shifting into the foreground is the rise of smaller LATAM markets -- and the operational positioning of new entrants like Chile and competitive challengers like Synvia.
Take a closer look at where early-phase work is actually moving. 👇
---
For first-in-human and early-feasibility studies enrolling cohorts of five to fifteen patients, operational agility is becoming the deciding factor in sponsor country selection. Reduced logistical complexity, faster ethics review, and streamlined coordination are now allowing El Salvador, Panama, and the Dominican Republic to deliver first-patient-in timelines that frequently outpace Brazil and Mexico. The pattern is consistent across MedTech, biopharma, and radiopharma sponsors operating in the region.
Why It Matters: For sponsors planning early-phase studies with small patient counts, the conventional case for the largest LATAM markets weakens significantly. Site activation speed and regulatory turnaround in smaller jurisdictions can deliver competitive timelines without the operational overhead of operating in the region's headline countries.
---
Chile is gaining visibility as a destination for first-in-human biopharma studies, with sponsors increasingly evaluating the country alongside more established regional research destinations. The operational case rests on three pillars: structured regulatory preparation under ISP, site strategy aligned with the country's tertiary-care network, and early planning around study execution that anticipates Decreto Exento 25 and 31 timelines. As the bioaccess(R) FIH country map widens, Chile now joins Argentina, Brazil, Colombia, the Mexico-Panama corridor, and Bolivia as a sixth credible LATAM jurisdiction for early-phase development.
Bottom Line: Sponsors evaluating Chile for first-in-human work should integrate regulatory preparation, site strategy, and ISP submission planning early in the protocol design phase -- not after CRO selection. The country's emerging FIH profile is built on operational sequencing, not on a single regulatory reform.
---
Beyond first-in-human biopharma specifically, Chile's broader clinical trial approval pathway is drawing increased interest from sponsors seeking efficient study startup. Ethics committee approvals, submission preparation, and site activation planning are the operational levers where ISP-jurisdiction trials are competing most directly with the region's faster jurisdictions. Although Chile lacks a statutory hard cap on regulatory review, the practical timelines have narrowed enough that the country is now part of the multi-country FIH conversation rather than an afterthought.
What to Focus On: ISP's approval pathway rewards sponsors who treat submission preparation as a coordinated workstream rather than a sequential filing. Studies that build ethics approval and ISP submission in parallel -- and that anticipate Chile's documentation requirements at protocol design -- consistently close the gap with Argentina and Brazil on study startup.
---
bioaccess(R) is the world's only CRO dedicated exclusively to first-in-human clinical trials in Latin America, helping MedTech, biopharma, and radiopharma sponsors compress timelines and reduce cost without compromising regulatory rigor.
Schedule your first-in-human trial consultation at bioaccessla.com.
---
The U.S. Food and Drug Administration has scheduled an industry information session on May 15 to discuss the structure of its Real-Time Clinical Trials pilot, with broader request-for-information comments open through May 29 and pilot site selection expected in July. The initiative is built on continuous data capture, ongoing monitoring, and rapid decision-making -- a structural shift in how trial infrastructure is designed and operated. Two proof-of-concept studies are already underway: AstraZeneca's Phase 2 TRAVERSE in mantle cell lymphoma and Amgen's Phase 1b STREAM-SCLC.
Why It Matters: Latin American sites participating in FDA-regulated programs need to begin evaluating their infrastructure for continuous data capture, EDC integration depth, and monitoring cadence well before the July selection window. The next round of competitive differentiation in the region is likely to be operational, not regulatory.
---
Brazilian CRO Synvia is now actively marketing an integrated model for Phase I and bioequivalence studies that combines clinical site operations, central and bioanalytical laboratories, regulatory affairs, and data intelligence under a single contract architecture. The timing is deliberate: Brazil's Law 14.874/2024 took full effect on April 28, and Synvia is positioning itself precisely as sponsors begin executing studies under the new framework. The model competes directly with international CROs entering the Brazilian market and with bridge-site operators marketing themselves as ANVISA-eligible alternatives.
Bottom Line: The domestic Brazilian CRO market is consolidating around integrated, single-contract architectures rather than disaggregated vendor networks. Sponsors planning Brazilian Phase I and bioequivalence work should evaluate domestic operators alongside international CROs -- the operational gap has narrowed enough that local execution capabilities now match the regulatory familiarity advantage.
---
CytomX Therapeutics announced the completion of dose optimization for its Phase 1 Varseta-M program, with 40 patients enrolled to date. Additional data expected later this year will inform monotherapy dose selection and registrational design in late-line colorectal cancer. The program -- an EpCAM PROBODY antibody-drug conjugate -- adds to continued momentum in ADC research, one of the fastest-growing segments in oncology drug development. The Phase 1 work is currently US-sited; the eventual registrational study is the inflection point for potential LATAM site expansion.
What to Focus On: ADC sponsors moving from Phase 1 to registrational design are the highest-value pipeline for LATAM site networks. CytomX's Varseta-M timeline -- monotherapy dose selection in H2 2026, registrational planning to follow -- is the kind of program profile where LATAM operational advantages compound across recruitment speed, patient diversity, and cost structure.
---
---
bioaccess(R) | Fast-Tracking First-in-Human Trials, Anywhere.
Follow us on LinkedIn | Subscribe to Global Trial Accelerators(TM)
← All Global Trial Accelerators editions · Contact bioaccess®